

APR 12 2011

Section 8**510(k) - Summary**

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.

I. GENERAL INFORMATION**1. Device Name and Classification**

Product Name: *syngo.CT Cardiac Function*
Classification Name: Accessory to Computed Tomography System
Classification Panel: Radiology
CFR Section: 21 CFR §892.1750
Device Class: Class II
Product Code: 90 JAK

2. Importer/Distributor Establishment:

Registration Number: 2240869

Siemens Medical Solutions, Inc.
51 Valley Stream Pkwy
Malvern, PA 19355

3. Manufacturing Facility:

Siemens AG
Medical Solutions
Henkestrasse 127
D-91052 Erlangen, Germany

4. Contact Person:

Mr. Ralf Hofmann
Regulatory Affairs Specialist
Siemensstr.1; D-91301 Forchheim
Phone: +49 9191 18-8170
Fax: +49 9191 18-9782

5. Date of Preparation of Summary: Mar. 23rd 2011

II. SAFETY AND EFFECTIVENESS INFORMATION SUPPORTING THE SUBSTANTIAL EQUIVALENCE DETERMINATION

6. General Safety and Effectiveness Concerns:

The device labeling contains instructions for use and any necessary cautions and warnings, to provide for safe and effective use of the device.

Risk management is ensured via a hazard analysis, which is used to identify potential hazards. These potential hazards are controlled via software development, verification and validation testing. To minimize electrical, mechanical, and radiation hazards, Siemens adheres to recognized and established industry practice and standards.

7. Device Description and Intended Use:

Syngo.CT Cardiac Function is an image analysis software package for evaluating cardiac CT angiography (CTA) volume data sets. Combining digital image processing and visualization tools (multiplanar reconstruction (MPR) thin/thick, minimum intensity projection (MIP) thin/thick, inverted MIP thin/thick, volume rendering technique (VRT)), evaluation tools (left and right ventricular (LV/RV) volume calculation, left ventricular myocardial wall calculation and visualization of myocardial enhancement by color coding of hypo-/hyperdense areas) and reporting tools (finding location, finding characteristics and key images), the software package is designed to support the physician in determining the functional parameters of the left and right ventricles, confirming the presence or absence of physician-identified myocardial enhancement defects and evaluation, documentation and follow-up of any such finding.

These visualization/evaluation tools allow for quantification of functional parameters and characterization of myocardial enhancements defects over time, helping the physician to assess any changes. It is also designed to help the physician classify conspicuous regions of tissue.

8. Substantial Equivalence:

syngo.CT Cardiac Function software package, designed for post processing images that have been continuously acquired with computed tomography (CT) imaging systems which meet certain minimal requirements, is substantially equivalent to the following devices:

<u>Manufacturer</u>	<u>Product</u>	<u>510(k)</u>	<u>Clearance date</u>
1. Siemens AG	syngo® Circulation	K063762	01/05/2007
2. Siemens AG	syngo®.x	K092519	08/27/2009
4. GE Medical Systems	CardIQ Function Xpress	K073153	02/26/2008
5. GE Medical Systems	CardIQ Xpress 2.0	K073138	02/26/2008

9. Summary of Technological Characteristics of the Principle Device as Compared with the Predicate Devices

syngo.CT Cardiac Function is a post-processing software package which provides a combination of functionality similar to functionality provided by one or more of the predicate devices as listed below. It uses the same data for evaluation as the predicate devices and provides results in the same format as the predicate devices.

As basis for data viewing, *syngo.CT Cardiac Function* uses basic reader and image display functionality as provided by syngo[®].x. In addition to basic viewing capabilities, *syngo.CT Cardiac Function* provides tools for visualization, analysis and reporting of cardiac function conditions. These tools are based on segmentation of cardiovascular structures such as coronary arteries and heart chambers. Accordingly, *syngo.CT Cardiac Function* has equivalent technological characteristics as the predicate devices. Moreover, *syngo.CT Cardiac Function* uses current image processing algorithms, in order to provide results that are substantially equivalent to those obtained with one or more of the predicate devices.

<i>syngo.CT Cardiac Function</i>	Description	Comparison to predicate devices
Basic Reading Functionality	Conventional navigation on 2D and 3D views, change of layouts, adapt window values	Same
Cardiac, Aortic Valve and Mitral Valve Planes	Rotate MPR planes to short/long axis, aortic or mitral plane views	Extended: Additional planes for aortic and mitral valve.
Review Marker	Functionality for setting location of a clinical finding on any view	Extended. Additional bookmarking functionality.
Integrated Reporting (Reporting Tools)	Functionality for editing values of clinical findings such as location, pathology, etc	Same
Heart Isolation	Masking of structures around the heart	Same
4D Movie and Movie Series	Start/stop movie and adjust all views. Select MPR views for movie series	Extended. Storage for movie series added.
4D Chamber Modeling and Contouring	Contouring of heart chambers contours, edit and correction of contouring	Extended. Added editing functions.
4D Left Ventricle Analysis	Volumetry of left ventricle over complete heart cycle. Selection of volumetry mode.	Extended. Added support for dual analysis mode.
Dynamic Volume Graph	Volume graph over heart cycle.	Same
Functional Parameters	Measurement of global and local cardiac function parameters.	Extended. Additional display options.
Polar Maps	Bulls-eye plots for display of local cardiac function parameters.	Same
4D Right Ventricular Analysis	Volumetry of right ventricle over complete heart cycle.	Same
Visualization of relative Enhancement in Myocardium	Colouring of left ventricular myocardium based on relative HU enhancement.	Same
Delayed Relative Enhancement View	Colouring of left ventricular myocardium based on HU enhancement.	Same
Hybrid View	VRT visualization of coronary anatomy combined with local functional parameters in a single view.	Extended. Left ventricular epicardial model added to VRT.
DICOM compatible		Same

Siemens is of the opinion that *syngo.CT Cardiac Function* software package is intended for the same indications for use as the predicate devices. It does not introduce any new potential safety risk and is substantial equivalent to and performs as well as the predicate devices.

10. Summary of non-clinical and/or clinical testing

syngo.CT Cardiac Function is designed to fulfill the requirements of following standards

- IEC 60601-1-6 : 2006; Medical electrical equipment - Part 1-6: General requirements for basic safety and essential performance - Collateral Standard: Usability
- IEC 62304 Ed. 1.0, "Medical Device Software – Software Lifecycle Processes"
- ISO 14971:2007; Medical devices - Application of risk management to medical devices
- DICOM (Digital Imaging and Communications in Medicine) Standard: 2008
DICOM conformity is fully covered by syngo[®].x implementations.

Non clinical tests are conducted for *syngo.CT Cardiac Function* software package during product development. The Risk analysis was completed and risk control implemented to mitigate identified hazards. The testing results supports that all the software specifications have met the acceptance criteria.

Testing for verification and validation of the device was found acceptable to support the claims of substantial equivalence.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room – WO66-G609
Silver Spring, MD 20993-0002

Siemens AG Medical Solutions
% Mr. Norbert Stuiber
Responsible Third Party Official, 510(k) TPR Program Manager
TÜV SÜD America
1775 Old Hwy 8 NW, Ste 104
NEW BRIGHTON MN 55112-1891

Re: K110366

APR 12 2011

Trade/Device Name: syngo.CT Cardiac Function
Regulation Number: 21 CFR 892.1750
Regulation Name: Computed tomography x-ray system
Regulatory Class: II
Product Code: JAK
Dated: April 4, 2011
Received: April 7, 2011

Dear Mr. Stuiber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely Yours,



Mary S. Pastel, Sc.D.
Director
Division of Radiological Devices
Office of In Vitro Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indication for use

510(k) Number (if known): K110366

Device Name: **syngo.CT Cardiac Function**


Syngo.CT Cardiac Function is an image analysis software package for evaluating cardiac CT angiography (CTA) volume data sets. Combining digital image processing and visualization tools (multiplanar reconstruction (MPR) thin/thick, minimum intensity projection (MIP) thin/thick, inverted MIP thin/thick, volume rendering technique (VRT)), evaluation tools (left and right ventricular (LV/RV) volume calculation, left ventricular myocardial wall calculation and visualization of myocardial enhancement by color coding of hypo-/hyperdense areas) and reporting tools (finding location, finding characteristics and key images), the software package is designed to support the physician in determining the functional parameters of the left and right ventricles, confirming the presence or absence of physician-identified myocardial enhancement defects and evaluation, documentation and follow-up of any such finding.

These visualization/evaluation tools allow for quantification of functional parameters and characterization of myocardial enhancements defects over time, helping the physician to assess any changes. It is also designed to help the physician classify conspicuous regions of tissue.

Prescription Use AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of the CDRH, Office of In Vitro Diagnostic Devices (OIVD)



Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K110366